ReviewBiomolecules2026
Overcoming the Druggability Hurdles of Celastrol: A Critical Review of Advanced Drug Delivery Strategies.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Celastrol, one of the top five traditional natural products with high potential for modern drug development, exerts potent broad-spectrum biological activities, yet its poor aqueous solubility, low bioavailability, potential toxicity, and limited selectivity severely compromise its drug-likeness. Advanced drug delivery strategies, mainly including multifunctional polymer/lipid/protein-based organic nanoparticles, metal/silica-based inorganic nanoparticles, vesicles represented by liposomes, and nanoemulsions, are expected to overcome these druggability hurdles of celastrol via oral, transdermal or intravenous administration. This review summarizes recent progress in a series of celastrol formulations, including novel dosage forms and delivery routes accompanied with consequential pharmacological effects and mechanisms of action, which have the potential to bring about better druggability conducive to future medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.